Protein Engineering, Vol. 13, No. 8, 583-588,
August 2000
© 2000 Oxford University Press
Construction of a diabody (small recombinant bispecific antibody) using a refolding system
1 First Department of Surgery, School of Medicine, Tohoku University, Sendai, 2 Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 3 Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan, and 4 Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
Diabodies are the recombinant bispecific antibodies (BsAbs), constructed from heterogeneous single-chain antibodies. Usually, diabodies have been prepared from bacterial periplasmic fraction using a co-expression vector (i.e. genes encoding two chains were tandemly located under the same promoter). Some diabodies, however, cannot be expressed as a soluble material owing to inclusion body formation, which limits the utilization of diabodies in various fields. Here we report an improved method for the construction of diabodies using a refolding system. As a model, a bispecific diabody binding to adenocarcinoma-associated antigen MUC1 and to CD3 on T cells was studied. One chain consisted of a VH specific for MUC1 linked to a VL specific for CD3 with a short polypeptide linker (GGGGS). The second was composed of a VL specific for MUC1 linked to a VH specific for CD3. The two hetero scFvs were independently obtained from intracellular insoluble fractions of Escherichia coli, purified, mixed stoichiometrically (at an equivalent molar ratio of 1:1) and refolded. The refolded two hetero scFv has a hetero-dimeric structure, with complete specificity for both target cells [i.e. MUC1 positive cells and CD3 positive lymphokine-activated killer cells with a T cell phenotype (T-LAK)]. Evaluation of the in vitro efficacy of T-LAK with the diabody by growth inhibition assay of cancer cells demonstrated maximum growth inhibition of cancer cells to reach ~98% at an effector:target ratio (E:T ratio) of 10, almost identical with that with anti-MUC1xanti-CD3 chemically synthesized BsAbs (c-BsAbs). This is the first report of the construction of a diabody using a refolding system.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Asano, Y. Sone, K. Ikoma, H. Hayashi, T. Nakanishi, M. Umetsu, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528 Protein Eng. Des. Sel., July 11, 2008; (2008) gzn037v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Asano, Y. Watanabe, H. Kawaguchi, H. Fukazawa, T. Nakanishi, M. Umetsu, H. Hayashi, Y. Katayose, M. Unno, T. Kudo, et al. Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells J. Biol. Chem., September 21, 2007; 282(38): 27659 - 27665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Asano, Y. Sone, K. Makabe, K. Tsumoto, H. Hayashi, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Humanization of the Bispecific Epidermal Growth Factor Receptor x CD3 Diabody and Its Efficacy as a Potential Clinical Reagent. Clin. Cancer Res., July 1, 2006; 12(13): 4036 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akifusa, W. Heywood, S. P. Nair, G. Stenbeck, and B. Henderson Mechanism of internalization of the cytolethal distending toxin of Actinobacillus actinomycetemcomitans Microbiology, May 1, 2005; 151(5): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akifusa, S. Poole, J. Lewthwaite, B. Henderson, and S. P. Nair Recombinant Actinobacillus actinomycetemcomitans Cytolethal Distending Toxin Proteins Are Required To Interact To Inhibit Human Cell Cycle Progression and To Stimulate Human Leukocyte Cytokine Synthesis Infect. Immun., September 1, 2001; 69(9): 5925 - 5930. [Abstract] [Full Text] [PDF]
|
|